The global anti-fungal therapy market valuation was USD 13.8 billion in 2022 and is expected to expand at a CAGR of 4.7% from 2023 to 2033. The market is projected to reach USD 22.8 billion by 2033. The azoles segment is leading the market by drug class with a share of about 29.1% in 2022.
| Data Points | Market Insights |
|---|---|
| Anti-fungal Therapy Market Size, 2022 | USD 13.8 Billion |
| Anti-fungal Therapy Market Value, 2023 | USD 14.4 Billion |
| Anticipated Market Value, 2033 | USD 22.8 Billion |
| Value-based CAGR (2023 to 2033) | 4.7% |
| Market Share of Top 5 Countries | 52.3% |
| Key Market Players | Eli Lilly and Company, Sanofi S.A, Abbott Laboratories, Arcadia Consumer Healthcare Inc., Astellas Pharma Inc, GlaxoSmithKline Plc, Merck & Co. Inc., Novartis A.G, Gilead Sciences Inc., Johnson & Johnson’s, MerzPharma, Enzon Pharmaceuticals Inc., Glenmark, Dr. Reddy's Laboratories, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd., Apotex Inc., Zydus Cadila, Aurobindo Pharma, Cipla Inc., Dr. Reddy's Laboratories Ltd., Pfizer Inc., Torrent Pharmaceuticals Ltd., Bayer AG. |
Rapid initiation of antifungal therapy is essential in the management of fungal diseases that target either the plasma membrane or the cell wall. Increasing perception rates of primary classes of antifungal agents act as a driver for the growth of the antifungal drugs and therapies market.
The efforts of government and private organizations to raise awareness about various fungal illnesses are projected to boost the anti-fungal drugs market. Furthermore, an increase in fungal infection cases such as aspergillosis and candidiasis is one of the major reasons driving the growth of the anti-microbial/anti-fungal test market.
The market share for anti-fungal therapies was around 30.8% of the overall global antibiotics market, which was worth USD 42.5 billion in 2022. The market grew at a CAGR of 3.0% during the historical period.
| Historical CAGR (2017 to 2022) | 3.0% |
|---|
The demand for anti-fungal therapies expanded at a CAGR of 4.7% from 2023 to 2033, owing to the rising cases of fungal diseases like candidiasis, aspergillosis and onychomycosis.Anti-fungal therapies are widely employed in the mycosis control and treatment/mycosis management market.
People are looking for products that would promote faster recovery and prevention of fungal diseases. Over the forecast period, the market is projected to be driven by the pharmaceutical industries’ formulations and the ongoing developments in the discovery of novel treatments for fungal diseases.
For instance, on 7 June 2022, the USA Food and Drug Administration (FDA) approved the use of Sanofi Dupixent (dupilumab) for children who are six months to 5 years old with moderate-to-severe atopic dermatitis.
Furthermore, the market for anti-fungal therapies is growing due to rising new drug development and clinical trials activities. For instance, three novel antifungals are undergoing phase II and phase III clinical studies, namely rezafungin, olorofim, and fosmanogepix by Amplyx Pharmaceuticals, which were acquired by Pfizer in April 2022.
The market is anticipated to grow as a result of an increase in initiatives by private and public organizations to spread awareness about a variety of fungal illnesses. For instance, CDC (Centres For Disease Control And Prevention) and its partners organized Fungal Disease Awareness Week, September 20-24, 2022. The purpose of this program is to highlight the importance of detecting and diagnosing serious fungal diseases early in patients to provide life-saving treatment.
Fungal infections of the eyes, mouth, and skin, including superficial and systematic infections, are projected to fuel market expansion. The availability and effective adoption of generic antifungal drugs like miconazole, clotrimazole, and econazole for the treatment of fungal infections create significant opportunities in the market. Anti-fungal therapies that doctors strongly prescribe for patients to treat fungal infections are also considered one of the key factors in boosting the market.
Sometimes, antifungal therapy is harmful to the patient and causes side effects such as heart arrhythmia, oliguria, promethazine and muscle spasms or pain. For instance, according to the National Library of Medicine, amphotericin B deoxycholate therapy is known to cause side effects like chills, the risk of hypotension, migraines, hypomagnesemia, renal insufficiency, emesis, rigors, and pyrexia.
The market is expected to be hampered by strict government regulations, patent expirations, an increase in fungal resistance to drugs, etc., during the projected period. Furthermore, it is anticipated that rising drug recall rates may hamper the market's expansion. These factors cumulatively propose a negative effect on the growth of the anti-fungal therapy market.
| Country | CAGR (2023 to 2033) |
|---|---|
| United States | 4.8% |
| India | 4.2% |
| China | 4.4% |
| Germany | 3.8% |
| United Kingdom | 3.9% |
The United States anti-fungal therapy market is expected to grow at a CAGR of 4.8% over the forecast period.
A major driver of the market expansion for anti-fungal therapies in the United States is the rising prevalence of fungal infections among people. For instance, according to Oxford University Press, 666,235 cases of fungal infections were identified in the United States. Infections with pneumocystis, candida, and aspergillus accounted for 76.3% of reported fungal infections and 81.1% of related treatment costs.
Key players in the United States engage in non-organic actions, such as mergers and acquisitions, to expand their antifungal therapy drug portfolio. This is a key element driving the demand for antifungal medications in the USA
Germany held around 32.9% share of the European market in 2022, due to the prevalence of allergic fungal diseases like aspergillosis and dermatophytosis. The market in Germany is expected to grow at a CAGR of 3.8% through 2033.
Fungal infections are considered a significant public health issue in Germany. Germany will see profitable growth as more and more pharmaceutical drugs are manufactured for various fungal diseases. For instance, in 2018, Pfizer started new manufacturing units for anti-fungal medicines in Germany.
In addition, the provision of public health advocacy for people with fungal diseases is another area where the government and other private groups are investing heavily, and it is anticipated to drive the market for anti-fungal therapies in Germany.
The market in India is set to exhibit a CAGR of 4.2% over the forecast period.
In India, strong financing and the launch of several healthcare programs like Pradhan Mantri Jan Arogya Yojana and Ayushman Bharat offer free healthcare facilities and reimbursement options to patients receiving healthcare treatment. This is boosting the demand for anti-fungal therapy market.
Increasing disposable incomes of middle-class families enable them to spend more money on their healthcare expenditure to get high-quality treatment facilities. The market is expected to grow more quickly throughout the forecast period due to increased expenditure on continued research and development for anti-fungal drug innovations. Increasing awareness of fungal infection and the adoption of antifungal drugs are driving the anti-fungal therapy market.
The market in the United Kingdom is expected to rise at a CAGR of 3.9% through 2033.
In the United Kingdom, accessibility of antifungal drugs and rising awareness among healthcare professionals are expected to drive the market in the United Kingdom. The United Kingdom has a well-established healthcare system, and antifungal therapies are prescribed to patients only by healthcare professionals.
The market in China is expected to rise at a CAGR of 4.4% through 2033. Rapid urbanization, evolving lifestyle, and increasing healthcare awareness boost sales of antifungal drugs in China. Also, the healthcare system in China has been evolving, and access to healthcare services has improved in recent years.
| Top Drug Class | Azoles |
|---|---|
| Market Share | 29.1% |
Azoles constitute a share of 29.1% of the anti-fungal therapy industry share by drug class. The increasing cases of fungal diseases like blastomycosis, histoplasmosis, and ringworm are contributing to market expansion. Azoles prevent the formation of fungus sterols. Azole antifungal agents help in the treatment of systemic fungal infections, contributing to market expansion.
| Top Indication | Candidiasis |
|---|---|
| Market Share | 35.0% |
The candidiasis segment holds a share of 35.0% of the market by indication. The most common fungal infection is candidiasis, which is caused by yeast. The rising cases of candidiasis are driving the anti-fungal therapy market.
| Top Route of Administration | Topical |
|---|---|
| Market Share | 53.7% |
The topical route of administration of drugs is more preferred by patients compared to oral and parenteral. The topical segment holds a prominent market share of 53.7%, rising at a CAGR of 4.7% over the forecast period. Topical formulation is less expensive than oral formulation and has fewer adverse side effects. Also, the topical route of administration has a higher retention rate and direct access, further propelling the demand for anti-fungal therapies.
| Top Distribution Channel | Retail Pharmacies |
|---|---|
| Market Share | 44.0% |
Retail pharmacies hold a prominent share of 44.0% of the market by distribution channels. The growing prevalence of antifungal infections like dermatophytosis, aspergillus, and superficial mycoses and the developments in drug discovery have driven this segment’s growth, propelling the anti-fungal therapy market.
The market for the production of anti-fungal therapies/drugs is fragmented due to the presence of several key players. These businesses are employing strategies including collaborations, partnerships, mergers and acquisitions, and new product launches to satisfy consumer demand and increase their client base. Also, governments are focusing on taking initiatives to invest in mobility equipment and enhance the anti-fungal drug and therapy market dynamics.
Recent Developments in the Anti-fungal Therapy Market
Similarly, more recent developments related to anti-fungal therapies/drugs have been tracked by the team at Future Market Insights, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2017 to 2022 |
| Market Analysis | USD Billion for Value |
| Key Regions Covered | North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, UK, Germany, Italy, Russia, Spain, France, BENELUX, Nordic countries, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC, Israel, South Africa and North Africa |
| Key Market Segments Covered | Drug Class, Indication, Route of Administration, Distribution Channel and Region |
| Key Companies Profiled | Eli Lilly and Company, Sanofi S.A, Abbott Laboratories, Arcadia Consumer Healthcare Inc., Astellas Pharma Inc, GlaxoSmithKline Plc, Merck & Co. Inc., Novartis A.G, Gilead Sciences Inc., Johnson & Johnson’s, MerzPharma, Enzon Pharmaceuticals Inc., Glenmark, Dr. Reddy's Laboratories, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd., Apotex Inc., Zydus Cadila, Aurobindo Pharma, Cipla Inc., Dr. Reddy's Laboratories Ltd., Pfizer Inc., Torrent Pharmaceuticals Ltd., Bayer AG |
| Pricing | Available upon Request |
Table 01: Global Market PR Size (US$ Billion) Analysis and Forecast 2023 to 2033, By Drug Class
Table 02: Global Market PR Size (US$ Billion) Analysis and Forecast 2023 to 2033, By Indication
Table 03: Global Market PR Size (US$ Billion) Analysis and Forecast 2023 to 2033, By Route of Administration
Table 04: Global Market PR Value (US$ Billion) Analysis and Forecast 2023 to 2033, By Distribution Channel
Table 05: Global Market PR Size (US$ Billion) Analysis and Forecast 2023 to 2033, By Region
Table 06: North America Market PR Size Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
Table 07: North America Market PR Size Analysis 2017 to 2022 and Forecast 2023 to 2033, By Drug Class
Table 08: North America Market PR Size Analysis 2017 to 2022 and Forecast 2023 to 2033, By Indication
Table 09: North America Market PR Size Analysis 2017 to 2022 and Forecast 2023 to 2033, By Route of Administration
Table 10: North America Market PR Size Analysis 2017 to 2022 And Forecast 2023 to 2033, By Distribution Channel
Table 11: Latin America Market PR Size Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
Table 12: Latin America Market PR Size Analysis 2017 to 2022 and Forecast 2023 to 2033, By Drug Class
Table 13: Latin America Market PR Size Analysis 2017 to 2022 and Forecast 2023 to 2033, By Indication
Table 14: Latin America Market PR Size Analysis 2017 to 2022 and Forecast 2023 to 2033, By Route of Administration
Table 15: Latin America Market PR Size Analysis 2017 to 2022 and Forecast 2023 to 2033, By Distribution Channel
Table 16: Europe Market PR Size Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
Table 17: Europe Market PR Size Analysis 2017 to 2022 and Forecast 2023 to 2033, By Drug Class
Table 18: Europe Market PR Size Analysis 2017 to 2022 and Forecast 2023 to 2033, By Indication
Table 19: Europe Market PR Size Analysis 2017 to 2022 and Forecast 2023 to 2033, By Route of Administration
Table 20: Europe Market PR Size Analysis 2017 to 2022 and Forecast 2023 to 2033, By Distribution Channel
Table 21: South Asia Market PR Size Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
Table 22: South Asia Market PR Size Analysis 2017 to 2022 and Forecast 2023 to 2033, By Drug Class
Table 23: South Asia Market PR Size Analysis 2017 to 2022 and Forecast 2023 to 2033, By Indication
Table 24: South Asia Market PR Size Analysis 2017 to 2022 and Forecast 2023 to 2033, By Route of Administration
Table 25: South Asia Market PR Size Analysis 2017 to 2022 and Forecast 2023 to 2033, By Distribution Channel
Table 26: East Asia Market PR Size Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
Table 27: East Asia Market PR Size Analysis 2017 to 2022 and Forecast 2023 to 2033, By Drug Class
Table 28: East Asia Market PR Size Analysis 2017 to 2022 and Forecast 2023 to 2033, By Indication
Table 29: East Asia Market PR Size Analysis 2017 to 2022 and Forecast 2023 to 2033, By Route of Administration
Table 30: East Asia Market PR Size Analysis 2017 to 2022 and Forecast 2023 to 2033, By Distribution Channel
Table 31: Oceania Market PR Size Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
Table 32: Oceania Market PR Size Analysis 2017 to 2022 and Forecast 2023 to 2033, By Drug Class
Table 33: Oceania Market PR Size Analysis 2017 to 2022 and Forecast 2023 to 2033, By Indication
Table 34: Oceania Market PR Size Analysis 2017 to 2022 and Forecast 2023 to 2033, By Route of Administration
Table 35: Oceania Market PR Size Analysis 2017 to 2022 and Forecast 2023 to 2033, By Distribution Channel
Table 36: Middle East & Africa Market PR Size Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
Table 37: Middle East & Africa Market PR Size Analysis 2017 to 2022 and Forecast 2023 to 2033, By Drug Class
Table 38: Middle East & Africa Market PR Size Analysis 2017 to 2022 and Forecast 2023 to 2033, By Indication
Table 39: Middle East & Africa Market PR Size Analysis 2017 to 2022 and Forecast 2023 to 2033, By Route of Administration
Table 40: Middle East & Africa Market PR Size Analysis 2017 to 2022 and Forecast 2023 to 2033, By Distribution Channel
Figure 01: Global Market PR Value Analysis (US$ Billion), 2014 to 2022
Figure 02: Global Market PR Value Forecast (US$ Billion), 2022 to 2033
Figure 03: Global Market PR Absolute $ Opportunity, 2022 to 2033
Figure 04: Global Market PR Share Analysis (%), By Drug Class, 2023 & 2033
Figure 05: Global Market PR Y-O-Y Analysis (%), By Drug Class, 2023 to 2033
Figure 06: Global Market PR Attractiveness Analysis By Drug Class, 2023 to 2033
Figure 07: Global Market PR Share Analysis (%), By Indication, 2023 & 2033
Figure 08: Global Market PR Y-O-Y Analysis (%), By Indication, 2023 to 2033
Figure 09: Global Market PR Attractiveness Analysis By Indication, 2023 to 2033
Figure 10: Global Market PR Share Analysis (%), By Route of Administration, 2023 & 2033
Figure 11: Global Market PR Y-O-Y Analysis (%), By Route of Administration, 2023 to 2033
Figure 12: Global Market PR Attractiveness Analysis By Route of Administration, 2023 to 2033
Figure 13: Global Market PR Share Analysis (%), Distribution Channel, 2023 & 2033
Figure 14: Global Market PR Y-O-Y Analysis (%), Distribution Channel, 2023 to 2033
Figure 15: Global Market PR Attractiveness Analysis Distribution Channel, 2023 to 2033
Figure 16: Global Market PR Share Analysis (%), By Region, 2023 & 2033
Figure 17: Global Market PR Y-O-Y Analysis (%), By Region, 2023 to 2033
Figure 18: Global Market PR Attractiveness Analysis By Region, 2023 to 2033
Figure 19: North America Market PR Value Share By Drug Class 2023 (E)
Figure 20: North America Market PR Value Share By Indication 2023 (E)
Figure 21: North America Market PR Value Share By Route of Administration 2023 (E)
Figure 22: North America Market PR Value Share Distribution Channel 2023 (E)
Figure 23: North America Market PR Value Share By Country 2023 (E)
Figure 24: North America Market PR Historical Market Size (US$ Billion) Analysis, 2014 to 2022
Figure 25: North America Market PR Current and Future Market Size (US$ Billion), 2022 to 2033 & Y-O-Y Growth Trend Analysis
Figure 26: North America Market PR Attractiveness Analysis By Drug Class, 2023 to 2033
Figure 27: North America Market PR Attractiveness Analysis By Indication, 2023 to 2033
Figure 28: North America Market PR Attractiveness Analysis By Route of Administration, 2023 to 2033
Figure 29: North America Market PR Attractiveness Analysis Distribution Channel, 2023 to 2033
Figure 30: North America Market PR Attractiveness Analysis By Country, 2023 to 2033
Figure 31: USA Market Value Proportion Analysis, 2022
Figure 32: USA Market PR Share Analysis (%), By Drug Class, 2022 & 2033
Figure 33: USA Market PR Share Analysis (%), By Indication, 2022 & 2033
Figure 34: USA Market PR Share Analysis (%), By Route of Administration, 2022 & 2033
Figure 35: USA Market PR Share Analysis (%), Distribution Channel, 2022 & 2033
Figure 36: Canada Market Value Proportion Analysis, 2022
Figure 37: Canada Market PR Share Analysis (%), By Drug Class, 2022 & 2033
Figure 38: Canada Market PR Share Analysis (%), By Indication, 2022 & 2033
Figure 39: Canada Market PR Share Analysis (%), By Route of Administration, 2022 & 2033
Figure 40: Canada Market PR Share Analysis (%), Distribution Channel, 2022 & 2033
Figure 41: Latin America Market PR Value Share By Drug Class 2023 (E)
Figure 42: Latin America Market PR Value Share By Indication 2023 (E)
Figure 43: Latin America Market PR Value Share By Route of Administration 2023 (E)
Figure 44: Latin America Market PR Value Share Distribution Channel 2023 (E)
Figure 45: Latin America Market PR Value Share By Country 2023 (E)
Figure 46: Latin America Market PR Historical Market Size (US$ Billion) Analysis, 2014 to 2022
Figure 47: Latin America Market PR Current and Future Market Size (US$ Billion), 2022 to 2033 & Y-O-Y Growth Trend Analysis
Figure 48: Latin America Market PR Attractiveness Analysis By Drug Class, 2023 to 2033
Figure 49: Latin America Market PR Attractiveness Analysis By Indication, 2023 to 2033
Figure 50: Latin America Market PR Attractiveness Analysis By Route of Administration, 2023 to 2033
Figure 51: Latin America Market PR Attractiveness Analysis Distribution Channel, 2023 to 2033
Figure 52: Latin America Market PR Attractiveness Analysis By Country, 2023 to 2033
Figure 53: Brazil Market Value Proportion Analysis, 2022
Figure 54: Brazil Market PR Share Analysis (%), By Drug Class, 2022 & 2033
Figure 55: Brazil Market PR Share Analysis (%), By Indication, 2022 & 2033
Figure 56: Brazil Market PR Share Analysis (%), By Route of Administration, 2022 & 2033
Figure 57: Brazil Market PR Share Analysis (%), Distribution Channel, 2022 & 2033
Figure 58: Mexico Market Value Proportion Analysis, 2022
Figure 59: Mexico Market PR Share Analysis (%), By Drug Class, 2022 & 2033
Figure 60: Mexico Market PR Share Analysis (%), By Indication, 2022 & 2033
Figure 61: Mexico Market PR Share Analysis (%), By Route of Administration, 2022 & 2033
Figure 62: Mexico Market PR Share Analysis (%), Distribution Channel, 2022 & 2033
Figure 63: Brazil Market Value Proportion Analysis, 2022
Figure 64: Brazil Market PR Share Analysis (%), By Drug Class, 2022 & 2033
Figure 65: Brazil Market PR Share Analysis (%), By Indication, 2022 & 2033
Figure 66: Brazil Market PR Share Analysis (%), By Route of Administration, 2022 & 2033
Figure 67: Brazil Market PR Share Analysis (%), Distribution Channel, 2022 & 2033
Figure 68: Argentina Market Value Proportion Analysis, 2022
Figure 69: Argentina Market PR Share Analysis (%), By Drug Class, 2022 & 2033
Figure 70: Argentina Market PR Share Analysis (%), By Indication, 2022 & 2033
Figure 71: Argentina Market PR Share Analysis (%), By Route of Administration, 2022 & 2033
Figure 72: Argentina Market PR Share Analysis (%), Distribution Channel, 2022 & 2033
Figure 73: Europe Market PR Value Share By Drug Class 2023 (E)
Figure 74: Europe Market PR Value Share By Indication 2023 (E)
Figure 75: Europe Market PR Value Share By Route of Administration 2023 (E)
Figure 76: Europe Market PR Value Share Distribution Channel 2023 (E)
Figure 77: Europe Market PR Value Share By Country 2023 (E)
Figure 78: Europe Market PR Historical Market Size (US$ Billion) Analysis, 2014 to 2022
Figure 79: Europe Market PR Current and Future Market Size (US$ Billion), 2022 to 2033 & Y-O-Y Growth Trend Analysis
Figure 80: Europe Market PR Attractiveness Analysis By Drug Class, 2023 to 2033
Figure 81: Europe Market PR Attractiveness Analysis By Indication, 2023 to 2033
Figure 82: Europe Market PR Attractiveness Analysis By Route of Administration, 2023 to 2033
Figure 83: Europe Market PR Attractiveness Analysis Distribution Channel, 2023 to 2033
Figure 84: Europe Market PR Attractiveness Analysis By Country, 2023 to 2033
Figure 85: Italy Market Value Proportion Analysis, 2022
Figure 86: Italy Market PR Share Analysis (%), By Drug Class, 2022 & 2033
Figure 87: Italy Market PR Share Analysis (%), By Indication, 2022 & 2033
Figure 88: Italy Market PR Share Analysis (%), By Route of Administration, 2022 & 2033
Figure 89: Italy Market PR Share Analysis (%), Distribution Channel, 2022 & 2033
Figure 90: Germany Market Value Proportion Analysis, 2022
Figure 91: Germany Market PR Share Analysis (%), By Drug Class, 2022 & 2033
Figure 92: Germany Market PR Share Analysis (%), By Indication, 2022 & 2033
Figure 93: Germany Market PR Share Analysis (%), By Route of Administration, 2022 & 2033
Figure 94: Germany Market PR Share Analysis (%), Distribution Channel, 2022 & 2033
Figure 95: UK Market Value Proportion Analysis, 2022
Figure 96: UK Market PR Share Analysis (%), By Drug Class, 2022 & 2033
Figure 97: UK Market PR Share Analysis (%), By Indication, 2022 & 2033
Figure 98: UK Market PR Share Analysis (%), By Route of Administration, 2022 & 2033
Figure 99: UK Market PR Share Analysis (%), Distribution Channel, 2022 & 2033
Figure 100: France Market Value Proportion Analysis, 2022
Figure 101: France Market PR Share Analysis (%), By Drug Class, 2022 & 2033
Figure 102: France Market PR Share Analysis (%), By Indication, 2022 & 2033
Figure 103: France Market PR Share Analysis (%), By Route of Administration, 2022 & 2033
Figure 104: France Market PR Share Analysis (%), Distribution Channel, 2022 & 2033
Figure 105: Spain Market Value Proportion Analysis, 2022
Figure 106: Spain Market PR Share Analysis (%), By Drug Class, 2022 & 2033
Figure 107: Spain Market PR Share Analysis (%), By Indication, 2022 & 2033
Figure 108: Spain Market PR Share Analysis (%), By Route of Administration, 2022 & 2033
Figure 109: Spain Market PR Share Analysis (%), Distribution Channel, 2022 & 2033
Figure 110: BENELUX Market Value Proportion Analysis, 2022
Figure 111: BENELUX Market PR Share Analysis (%), By Drug Class, 2022 & 2033
Figure 112: BENELUX Market PR Share Analysis (%), By Indication, 2022 & 2033
Figure 113: BENELUX Market PR Share Analysis (%), By Route of Administration, 2022 & 2033
Figure 114: BENELUX Market PR Share Analysis (%), Distribution Channel, 2022 & 2033
Figure 115: Nordic Countries Market Value Proportion Analysis, 2022
Figure 116: Nordic Countries Market PR Share Analysis (%), By Drug Class, 2022 & 2033
Figure 117: Nordic Countries Market PR Share Analysis (%), By Indication, 2022 & 2033
Figure 118: Nordic Countries Market PR Share Analysis (%), By Route of Administration, 2022 & 2033
Figure 119: Nordic Countries Market PR Share Analysis (%), Distribution Channel, 2022 & 2033
Figure 120: Russia Market Value Proportion Analysis, 2022
Figure 121: Russia Market PR Share Analysis (%), By Drug Class, 2022 & 2033
Figure 122: Russia Market PR Share Analysis (%), By Indication, 2022 & 2033
Figure 123: Russia Market PR Share Analysis (%), By Route of Administration, 2022 & 2033
Figure 124: Russia Market PR Share Analysis (%), Distribution Channel, 2022 & 2033
Figure 125: South Asia Market PR Value Share By Drug Class 2023 (E)
Figure 126: South Asia Market PR Value Share By Indication 2023 (E)
Figure 127: South Asia Market PR Value Share By Route of Administration 2023 (E)
Figure 128: South Asia Market PR Value Share Distribution Channel 2023 (E)
Figure 129: South Asia Market PR Value Share By Country 2023 (E)
Figure 130: South Asia Market PR Historical Market Size (US$ Billion) Analysis, 2014 to 2022
Figure 131: South Asia Market PR Current And Future Market Size (US$ Billion), 2022 to 2033 & Y-O-Y Growth Trend Analysis
Figure 132: South Asia Market PR Attractiveness Analysis By Drug Class, 2023 to 2033
Figure 133: South Asia Market PR Attractiveness Analysis By Indication, 2023 to 2033
Figure 134: South Asia Market PR Attractiveness Analysis By Route of Administration, 2023 to 2033
Figure 135: South Asia Market PR Attractiveness Analysis Distribution Channel, 2023 to 2033
Figure 136: South Asia Market PR Attractiveness Analysis By Country, 2023 to 2033
Figure 137: India Market Value Proportion Analysis, 2022
Figure 138: India Market PR Share Analysis (%), By Drug Class, 2022 & 2033
Figure 139: India Market PR Share Analysis (%), By Indication, 2022 & 2033
Figure 140: India Market PR Share Analysis (%), By Route of Administration, 2022 & 2033
Figure 141: India Market PR Share Analysis (%), Distribution Channel, 2022 & 2033
Figure 142: Indonesia Market Value Proportion Analysis, 2022
Figure 143: Indonesia Market PR Share Analysis (%), By Drug Class, 2022 & 2033
Figure 144: Indonesia Market PR Share Analysis (%), By Indication, 2022 & 2033
Figure 145: Indonesia Market PR Share Analysis (%), By Route of Administration, 2022 & 2033
Figure 146: Indonesia Market PR Share Analysis (%), Distribution Channel, 2022 & 2033
Figure 147: Malaysia Market Value Proportion Analysis, 2022
Figure 148: Malaysia Market PR Share Analysis (%), By Drug Class, 2022 & 2033
Figure 149: Malaysia Market PR Share Analysis (%), By Indication, 2022 & 2033
Figure 150: Malaysia Market PR Share Analysis (%), By Route of Administration, 2022 & 2033
Figure 151: Malaysia Market PR Share Analysis (%), Distribution Channel, 2022 & 2033
Figure 152: Thailand Market Value Proportion Analysis, 2022
Figure 153: Thailand Market PR Share Analysis (%), By Drug Class, 2022 & 2033
Figure 154: Thailand Market PR Share Analysis (%), By Indication, 2022 & 2033
Figure 155: Thailand Market PR Share Analysis (%), By Route of Administration, 2022 & 2033
Figure 156: Thailand Market PR Share Analysis (%), Distribution Channel, 2022 & 2033
Figure 157: East Asia Market PR Value Share By Drug Class 2023 (E)
Figure 158: East Asia Market PR Value Share By Indication 2023 (E)
Figure 159: East Asia Market PR Value Share By Route of Administration 2023 (E)
Figure 160: East Asia Market PR Value Share Distribution Channel 2023 (E)
Figure 161: East Asia Market PR Value Share By Country 2023 (E)
Figure 162: East Asia Market PR Historical Market Size (US$ Billion) Analysis, 2014 to 2022
Figure 163: East Asia Market PR Current And Future Market Size (US$ Billion), 2022 to 2033 & Y-O-Y Growth Trend Analysis
Figure 164: East Asia Market PR Attractiveness Analysis By Drug Class, 2023 to 2033
Figure 165: East Asia Market PR Attractiveness Analysis By Indication, 2023 to 2033
Figure 166: East Asia Market PR Attractiveness Analysis By Route of Administration, 2023 to 2033
Figure 167: East Asia Market PR Attractiveness Analysis Distribution Channel, 2023 to 2033
Figure 168: East Asia Market PR Attractiveness Analysis By Country, 2023 to 2033
Figure 169: China Market Value Proportion Analysis, 2022
Figure 170: China Market PR Share Analysis (%), By Drug Class, 2022 & 2033
Figure 171: China Market PR Share Analysis (%), By Indication, 2022 & 2033
Figure 172: China Market PR Share Analysis (%), By Route of Administration, 2022 & 2033
Figure 173: China Market PR Share Analysis (%), Distribution Channel, 2022 & 2033
Figure 174: Japan Market Value Proportion Analysis, 2022
Figure 175: Japan Market PR Share Analysis (%), By Drug Class, 2022 & 2033
Figure 176: Japan Market PR Share Analysis (%), By Indication, 2022 & 2033
Figure 177: Japan Market PR Share Analysis (%), By Route of Administration, 2022 & 2033
Figure 178: Japan Market PR Share Analysis (%), Distribution Channel, 2022 & 2033
Figure 179: South Korea Market Value Proportion Analysis, 2022
Figure 180: South Korea Market PR Share Analysis (%), By Drug Class, 2022 & 2033
Figure 181: South Korea Market PR Share Analysis (%), By Indication, 2022 & 2033
Figure 182: South Korea Market PR Share Analysis (%), By Route of Administration, 2022 & 2033
Figure 183: South Korea Market PR Share Analysis (%), Distribution Channel, 2022 & 2033
Figure 184: Oceania Market PR Value Share By Drug Class 2023 (E)
Figure 185: Oceania Market PR Value Share By Indication 2023 (E)
Figure 186: Oceania Market PR Value Share By Route of Administration 2023 (E)
Figure 187: Oceania Market PR Value Share Distribution Channel 2023 (E)
Figure 188: Oceania Market PR Value Share By Country 2023 (E)
Figure 189: Oceania Market PR Historical Market Size (US$ Billion) Analysis, 2014 to 2022
Figure 190: Oceania Market PR Current And Future Market Size (US$ Billion), 2022 to 2033 & Y-O-Y Growth Trend Analysis
Figure 191: Oceania Market PR Attractiveness Analysis By Drug Class, 2023 to 2033
Figure 192: Oceania Market PR Attractiveness Analysis By Indication, 2023 to 2033
Figure 193: Oceania Market PR Attractiveness Analysis By Route of Administration, 2023 to 2033
Figure 194: Oceania Market PR Attractiveness Analysis Distribution Channel, 2023 to 2033
Figure 195: Oceania Market PR Attractiveness Analysis By Country, 2023 to 2033
Figure 196: Australia Market Value Proportion Analysis, 2022
Figure 197: Australia Market PR Share Analysis (%), By Drug Class, 2022 & 2033
Figure 198: Australia Market PR Share Analysis (%), By Indication, 2022 & 2033
Figure 199: Australia Market PR Share Analysis (%), By Route of Administration, 2022 & 2033
Figure 200: Australia Market PR Share Analysis (%), Distribution Channel, 2022 & 2033
Figure 201: New Zealand Market Value Proportion Analysis, 2022
Figure 202: New Zealand Market PR Share Analysis (%), By Drug Class, 2022 & 2033
Figure 203: New Zealand Market PR Share Analysis (%), By Indication, 2022 & 2033
Figure 204: New Zealand Market PR Share Analysis (%), By Route of Administration, 2022 & 2033
Figure 205: New Zealand Market PR Share Analysis (%), Distribution Channel, 2022 & 2033
Figure 206: Middle East & Africa Market PR Value Share By Drug Class 2023 (E)
Figure 207: Middle East & Africa Market PR Value Share By Indication 2023 (E)
Figure 208: Middle East & Africa Market PR Value Share By Route of Administration 2023 (E)
Figure 209: Middle East & Africa Market PR Value Share Distribution Channel 2023 (E)
Figure 210: Middle East & Africa Market PR Value Share By Country 2023 (E)
Figure 211: Middle East & Africa Market PR Historical Market Size (US$ Billion) Analysis, 2014 to 2022
Figure 212: Middle East & Africa Market PR Current and Future Market Size (US$ Billion), 2022 to 2033 & Y-O-Y Growth Trend Analysis
Figure 213: Middle East & Africa Market PR Attractiveness Analysis By Drug Class, 2023 to 2033
Figure 214: Middle East & Africa Market PR Attractiveness Analysis By Indication, 2023 to 2033
Figure 215: Middle East & Africa Market PR Attractiveness Analysis By Route of Administration, 2023 to 2033
Figure 216: Middle East & Africa Market PR Attractiveness Analysis Distribution Channel, 2023 to 2033
Figure 217: Middle East & Africa Market PR Attractiveness Analysis By Country, 2023 to 2033
Figure 218: GCC Countries Market Value Proportion Analysis, 2022
Figure 219: GCC Countries Market PR Share Analysis (%), By Drug Class, 2022 & 2033
Figure 220: GCC Countries Market PR Share Analysis (%), By Indication, 2022 & 2033
Figure 221: GCC Countries Market PR Share Analysis (%), By Route of Administration, 2022 & 2033
Figure 222: GCC Countries Market PR Share Analysis (%), Distribution Channel, 2022 & 2033
Figure 223: Türkiye Market Value Proportion Analysis, 2022
Figure 224: Türkiye Market PR Share Analysis (%), By Drug Class, 2022 & 2033
Figure 225: Türkiye Market PR Share Analysis (%), By Indication, 2022 & 2033
Figure 226: Türkiye Market PR Share Analysis (%), By Route of Administration, 2022 & 2033
Figure 227: Türkiye Market PR Share Analysis (%), Distribution Channel, 2022 & 2033
Figure 228: South Africa Market Value Proportion Analysis, 2022
Figure 229: South Africa Market PR Share Analysis (%), By Drug Class, 2022 & 2033
Figure 300: South Africa Market PR Share Analysis (%), By Indication, 2022 & 2033
Figure 311: South Africa Market PR Share Analysis (%), By Route of Administration, 2022 & 2033
Figure 312: South Africa Market PR Share Analysis (%), Distribution Channel, 2022 & 2033
Figure 313: North Africa Market Value Proportion Analysis, 2022
Figure 314: North Africa Market PR Share Analysis (%), By Drug Class, 2022 & 2033
Figure 315: North Africa Market PR Share Analysis (%), By Indication, 2022 & 2033
Figure 316: North Africa Market PR Share Analysis (%), By Route of Administration, 2022 & 2033
Figure 317: North Africa Market PR Share Analysis (%), Distribution Channel, 2022 & 2033
The global anti-fungal therapy market was worth USD 13.8 billion in 2022 and is set to grow at a CAGR of 4.7% over the next ten years.
Rising prevalence of fungal infections such as candidiasis and adoption of anti-fungal therapies.
The United States, India, China, Germany, and the United Kingdom are expected to drive demand for anti-fungal therapies.
The market is expected to reach USD 22.8 billion by 2033, with sales revenue expected to register a 4.7% CAGR over the forecast period.
Demand for anti-fungal therapies in Europe is expected to register a growth rate of 4.2% through 2033.
The market in India is projected to grow at a CAGR of 4.2% over the forecast period.
Explore Therapy Area Insights
Anti-fungal Therapy Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
